| Ariad Treatment for Leukemia Shows Success Ariad unveiled updated trial data that show its treatment for patients with drug-resistant leukemia. online.wsj.com |
Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 (Business Wire) BURLINGTON, N.C.----Laboratory Corporation of America Holdings announced today that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below. us.rd.yahoo.com |
What Can Play Tricks on Your Memory Jeremy Singer-Vine summarizes new medical findings on false memory; muscle growth; walking speed and cognitive impairment; tai chi and fibromyalgia; autism; back pain. online.wsj.com |
Biodel's Linjeta Should Overcome the Usual FDA Approval Hurdles Joseph Krueger submits: Previously, I wrote an article about Biodel's (BIOD) VIAject (now called Linjeta), comparing its benefits to Mannkind’s (NASDAQ: MNKD) Afrezza. Linjeta is a more rapid-acting form of injectable human insulin for meal-time use by patients with Type 1 or Type 2 diabetes. Linjeta provides quicker glucose control than standard insulin, and also touts the benefits of reducing the usual weight gain and life-threatening hypoglycemic events seen in insulin users. Current insulin therapies are not delivered quickly enough to simulate the desired meal-time insulin spike. The formulation of insulin in Linjeta promotes a more rapid absorption, which more closely mirrors the effects of naturally produced insulin in non-diabetics, thereby providing more effective blood glucose control. In the article I discussed the potential problems facing Mannkind’s Afrezza approval and compared it to VIAject/Linjeta's potential approval. In the face of several recent panel reviews and/or FDA approvals having a poor outcome, I thought it would be a good time to re-visit this idea and discuss the prospects for Linjeta’s approval in light of several developments.Complete Story » seekingalpha.com |
Jiffy Lube Raises $1.1M for AHA - Video Jiffy Lube Surpasses $1 Million Fundraising Goal for the American Heart Association's Go Red For Women Movement to Fight Heart Disease feedproxy.google.com |